Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Schematic representation of RC48 structure and its targeting mechanism ...
The graphic illustration of the mechanism for RC48. RC48 exhibits the ...
RC48 inhibited the growth of HER2-positive colorectal cancer cells in ...
HER2-targeting antibody–drug conjugate RC48 alone or in combination ...
(PDF) HER2-targeting antibody–drug conjugate RC48 alone or in ...
(PDF) A HER2-targeting antibody-MMAE conjugate RC48 sensitizes ...
RC48 triggered cGAS-STING activation in colon cancer cells. A-C HCT116 ...
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in ...
Antitumor effect of RC48 in a hHER2+ mouse cancer cell. a Expression of ...
RC48 affects tumor growth in hHER2 xenograft breast cancer model and ...
Antitumor activity of immune checkpoint inhibitors and RC48 combination ...
RC48 strongly affects tumor growth in hHER2 xenograft breast cancer ...
Frontiers | The combination treatment of RC48 and STAT3 inhibitor acts ...
RC48 and PD-1/PD-L1 combination therapy affords long-lasting immune ...
Positive results from RC48 Clinical Trial in HER2-Positive Metastatic ...
Tumor immunostaining analysis after RC48 + PD-1/PD-L1 combined therapy ...
Antibody-drug Conjugates for HER2-Positive Gastric Cancer | Biopharma PEG
A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising ...
ASCO18中国之声│徐兵河教授团队：新药，RC48-ADC双周方案在晚期HER2阳性乳腺癌的疗效较好-肿瘤瞭望
【83】荣昌生物招股书解读之二：从RC48谈Her2靶向抗体偶联药物（ADC） 在上期和大家讨论了荣昌招股书的核心产品：治疗红斑狼疮的融合蛋白 ...
Frontiers | From AVATAR Mice to Patients: RC48-ADC Exerted Promising ...
RC48-ADC在HER2阳性局部晚期或转移性尿路上皮癌患者中活性的开放标签_治疗_研究_结果表明
A HER2‐targeted Antibody‐Drug Conjugate, RC48‐ADC, Exerted Promising ...
(PDF) Disitamab vedotin: a novel antibody-drug conjugates for cancer ...
The anticancer mechanism of RC48. HER2 is highly expressed on tumor ...
ASCO 2022: RC48-ADC For Metastatic Urothelial Carcinoma With HER2 ...
Inhibition of tumour-cell growth by RC48-ADC or antibody alone. A, HER2 ...
Table 1 from Open-label, Multicenter, Phase II Study of RC48-ADC, a ...
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting ...
(PDF) RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients ...
(PDF) Conjugating MMAE to a novel anti-HER2 antibody for selective ...
Oncology Letters
Frontiers | Combination treatment with anti-HER2 therapeutic antibody ...
Antibody Drug Conjugate Services | Biocytogen
Synergistic antitumor activity between HER2 antibody-drug conjugate and ...
RC48-C016: DV + Toripalimab Boosts Survival in HER2+ UC
ASCO 2019: A Phase II Study of RC48-ADC in HER2-Positive Patients with ...
曼话乳癌丨李曼教授：ADC药物在不同肿瘤治疗中“同工异曲”-肿瘤瞭望
Frontiers | Antibody-drug conjugates targeting HER2 for the treatment ...
ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in ...
Phase I study of the recombinant humanized anti-HER2 monoclonal ...
RC48-Antibody-Drug Conjugate in Metastatic Urothelial Carcinoma: A ...
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced ...
Frontiers | Partial response to trastuzumab deruxtecan (DS8201 ...
(PDF) RC48-ADC treatment for patients with HER2-expressing locally ...
FOXA1, induced by RC48, regulates HER2 transcription to enhance the ...
Distributions of naked antibodies and RC48-ADC in the lysosomes and ...
RC48-ADC monotherapy or in combination with immunotherapy for locally ...
从CSCO 2018上惊艳的RC48-ADC说起_尿路
Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy ...
ASCO中国之声丨徐兵河教授团队：首个中美突破性疗法认定维迪西妥单抗(RC48)成功定义HER2低表达mBC，ORR达40%！医药新闻 ...
(PDF) Disitamab Vedotin (RC48) combined with bevacizumab for treatment ...
SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting
Frontiers | Efficacy and safety of RC48-ADC in HER2-positive and HER2 ...
| RC48-ADC had superior antiproliferative effects than trastuzumab on 4 ...
(PDF) Phase I study of the recombinant humanized anti-HER2 monoclonal ...
Frontiers | Disitamab Vedotin (RC48) for HER2-positive advanced breast ...
Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
(PDF) Disitamab vedotin (RC48) plus toripalimab for HER2-expressing ...
抗癌新药，针对HER2的抗体偶联药RC48人体临床试验数据公布，疾病控制率近70%！_腾讯新闻
(PDF) Efficacy and safety of a novel anti‐HER2 therapeutic antibody ...
A phase II study of RC48-ADC in HER2-positive patients with locally ...
(PDF) RC48-ADC combined with tislelizumab as neoadjuvant treatment in ...
Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
Frontiers | mTOR inhibitor introduce disitamab vedotin (RC48-ADC ...
C014研究亚组ORR随HER2表达提高而 - 行业研究数据 - 小牛行研
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
(PDF) Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer ...
Clinical perspective: Antibody-drug conjugates for the treatment of ...
Novel development strategies and challenges for anti-Her2 antibody-drug ...
IND for RemeGen's Disitamab Vedotin Marks Important Milestone for the ...
Fabio Schutz on Twitter: "Dr. @MattGalsky discusses there abstracts ...
Next-generation antibody–drug conjugates revolutionize the precise ...
Overcoming immunotherapy resistance in bladder cancer with a novel ...
HER2-ADC: The first similar drug enters the market with a drop of 80% ...
靶向HER2！药物Enhertu显示出可以治疗多种类型肿瘤的迹象 - 知乎
(2).jpg&w=3840&q=75)
.png&w=3840&q=75)
(2).jpg&w=3840&q=75)
